Association of immune-checkpoint inhibitors and the risk of immune-related colitis among elderly patients with advanced melanoma: real-world evidence from the SEER–Medicare database

  • Abdulaali R. Almutairi (Contributor)
  • Marion Slack (Creator)
  • Brian L Erstad (Creator)
  • A. Mcbride (Creator)
  • I. Abraham (Creator)

Dataset

Description

Background:The use of anti-cytotoxic T-lymphocyte antigen 4 (anti-CTLA4) therapy (ipilimumab) and anti-programmed cell-death 1 (anti-PD1) agents (nivolumab and pembrolizumab) in advanced melanoma have been associated with immune-related adverse events (...
Date made available2021
PublisherSAGE Journals

Access Dataset

Cite this